NCT04207944 2025-06-15
The Prevention of Progression to Pancreatic Cancer Trial (The 3P-C Trial)
Duke University
Phase 2 Active not recruiting
Clinical Trials
13 trialsNCT04542135 2025-06-03
Sulindac and Breast Density in Women at Risk of Developing Breast Cancer
Stony Brook University
Phase 2 Completed
NCT01515137 2023-03-28
Study of TARCEVA (Erlotinib) as Adjuvant Treatment for Locally Advanced Head and Neck Squamous Cell Carcinoma
University of Pittsburgh
Phase 1 Completed
NCT01761877 2023-02-10
NSAID Effects on Clinical and Imaging Breast Biomarkers
Stony Brook University
Phase 2 Completed
NCT00299195 2020-11-19
A Randomized Study of Sulindac in Oral Premalignant Lesions
Memorial Sloan Kettering Cancer Center
Phase NA Completed
NCT00392665 2017-04-13
Bevacizumab/Tarceva and Tarceva/Sulindac in Squamous Cell Carcinoma of the Head and Neck
Massachusetts General Hospital
Phase 2 Terminated
NCT01843179 2017-02-17
Sulindac for Patients With AML
Massachusetts General Hospital
Phase 2 Withdrawn
NCT01187901 2016-06-17
FAPEST
University of Utah
Phase 2 Completed
NCT00039520 2014-05-06
Sulindac and Docetaxel in Treating Women With Metastatic or Recurrent Breast Cancer
Fox Chase Cancer Center
Phase 2 Completed
NCT00062023 2012-07-30
Comparison of Sulindac, Aspirin, and Ursodiol in Preventing Colorectal Cancer
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT00003365 2011-01-27
Sulindac and Plant Compounds in Preventing Colon Cancer
Rutgers, The State University of New Jersey
Phase NA Terminated
NCT00176618 2009-12-11
The Effects of Curcuminoids on Aberrant Crypt Foci in the Human Colon
Rutgers, The State University of New Jersey
Phase NA Terminated
NCT00319007 2007-08-10
Influence of Sulindac and Probiotics on the Development of Pouch Adenomas in Patients With Familial Adenomatous Polyposis
Radboud University Medical Center
Phase 2 Unknown